|
HBM Healthcare Investments AG
/ Key word(s): Acquisition/Partnership
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million
08.12.2025 / 14:50 CET/CEST
HBM Healthcare Investments, an investment company focused on the healthcare sector, announces that the shareholders of its privately held portfolio company Bluejay Therapeutics have approved a takeover by Mirum Pharmaceuticals (Nasdaq: MIRM). Under the terms of the definitive agreement, Mirum has agreed to acquire all outstanding shares of Bluejay for USD 250 million in cash and USD 370 million in Mirum common stock, plus potential tiered sales-based milestone payments of up to USD 200 million in cash.
HBM Healthcare Investments invested USD 7 million into the Series C financing round of Bluejay Therapeutics in May 2024. Upon completion of the transaction, HBM Healthcare Investments will receive approximately USD 6 million in cash and Mirum Pharmaceuticals shares currently valued at USD 7 million. Additional payments of up to USD 3.7 million may be received in the future upon the achievement of the sales-based milestones.
Bluejay Therapeutics develops therapies for viral and liver diseases. The company is testing brelovitug, an antibody for the treatment of chronic hepatitis D and hepatitis B viral infections.
End of Media Release
View original content: EQS News
|
| Language: |
English |
| Company: |
HBM Healthcare Investments AG |
|
Bundesplatz 1 |
|
6300 Zug |
|
Switzerland |
| Phone: |
+41438887171 |
| Fax: |
+41438887172 |
| E-mail: |
info@hbmhealthcare.com |
| Internet: |
https://www.hbmhealthcare.com |
| ISIN: |
CH0012627250 |
| Valor: |
1262725 |
| Listed: |
SIX Swiss Exchange |
| EQS News ID: |
2241904 |
| |
| End of News |
EQS News Service |
2241904 08.12.2025 CET/CEST
